SCHEMBL6714735

SCHEMBL6714735

Nc1ccc(N2CCc3ccccc3C2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.64
GRIN2D O15399 10/20 0.59
GRIN3B O60391 10/20 0.59
GRIN1 Q05586 10/20 0.59
GRIN2A Q12879 10/20 0.59
GRIN2B Q13224 10/20 0.59
GRIN2C Q14957 10/20 0.59
GRIN3A Q8TCU5 10/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
CHRM1 P11229 6/20 0.54
ADRA1D P25100 6/20 0.54
ADRA1A P35348 6/20 0.54
ADRA1B P35368 6/20 0.54
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
ADRA2C P18825 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375196 1.00 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6637762 0.87 EED (0.50) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL22466030 0.86 KMT2A (0.63) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2600447 0.84 EED (0.72) EEDGRIN2DGRIN3BGRIN1GRIN2A
Hydrochloric Acid SCHEMBL10535845 0.82 EED (0.70) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL10535865 0.81 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30101805 0.81 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL10534823 0.81 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL702928 0.81 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29836510 0.81 EED (0.64) EEDGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298155-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2022-09-22 US disclosed
US-11299487-B2 Compounds and compositions as modulators of TLR signaling NEUROPORE THERAPIES, INC. (US) 2022-04-12 US disclosed
US-20200308163-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2020-10-01 US disclosed
CN-101759637-B N-aryl-3,4-dihydro-isoquinoline salt and application thereof in preparing acaricidal and antibiotic medicament NORTHWEST A & F UNIVERSITY (CN) 2012-02-01 CN disclosed
CN-101759637-A N-aryl-3,4-dihydro-isoquinoline salt and application thereof in preparing acaricidal and antibiotic medicament UNIV NORTHWEST A&F 2010-06-30 CN disclosed
CN-1555260-A Aminoalkyl-substituted aromatic bicyclic compounds, process for their preparation and their use as pharmaceuticals ���ĵ�˹ҩ��¹����޹�˾ 2004-12-15 CN disclosed
US-20040198731-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-07 US disclosed
US-20040198732-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-07 US disclosed
US-20040198733-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-07 US disclosed
US-20040192693-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-30 US disclosed
US-20030212070-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298155-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 EED 3422/4885GRIN2D 825/4885GRIN3B 220/4885
US-20030212070-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals PER2, CNR2, DDC EED 2416/4885GRIN2D 454/4885GRIN3B 714/4885
US-20200308163-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 EED 3422/4885GRIN2D 825/4885GRIN3B 220/4885
US-20040192693-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals PER2, CNR2, DDC EED 2416/4885GRIN2D 454/4885GRIN3B 714/4885
US-20040198731-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals PER2, CNR2, DDC EED 2416/4885GRIN2D 454/4885GRIN3B 714/4885
US-20040198733-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals PER2, CNR2, DDC EED 2416/4885GRIN2D 454/4885GRIN3B 714/4885
US-20040198732-A1 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals PER2, CNR2, DDC EED 2416/4885GRIN2D 454/4885GRIN3B 714/4885
US-11299487-B2 Compounds and compositions as modulators of TLR signaling TLR3, TLR6, TLR4 EED 2753/4885GRIN2D 684/4885GRIN3B 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.